Trials / Terminated
TerminatedNCT03624907
Daily vs. Non-Daily SBRT for NSCLC
Consecutive Vs. Non-Consecutive Stereotactic Body Radiotherapy For Early Stage Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University of Florida · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if stereotactic body radiotherapy (SBRT) on non-consecutive days will increase the chances of curing non-small cell lung cancer when compared to daily treatment.
Detailed description
The purpose of this study is to determine if treatment with stereotactic body radiotherapy (SBRT) on non-consecutive days will improve the chance of curing non-small cell lung cancer compared to treatment with SBRT on consecutive days. In either case, the dose of radiation is the same. Non-consecutive treatments will be at least 40 hours apart and no more than 100 hours apart. The total course of treatment will be 8-12 days. Consecutive treatments will be daily over 4-5 days within one calendar week. The total course of treatment will be 4-5 days. The study team will assess if DNA from the tumor can be found in the blood to determine which patients respond quickest to radiotherapy. These results will not be made available to participants and will not change treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Daily Stereotactic Body Radiotherapy | After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion. |
| RADIATION | Non-Daily Stereotactic Body Radiotherapy | After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion. |
Timeline
- Start date
- 2018-10-19
- Primary completion
- 2021-06-16
- Completion
- 2021-06-16
- First posted
- 2018-08-10
- Last updated
- 2021-10-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03624907. Inclusion in this directory is not an endorsement.